Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Blood Vessels in Older Brains Break Down, Possibly Leading to Alzheimer’s

By Drug Discovery Trends Editor | January 22, 2015

University of Southern California (USC) neuroscientists may have unlocked another puzzle to preventing risks that can lead to Alzheimer’s disease. Researchers at Keck Medicine of USC used high-resolution imaging of the living human brain to show for the first time that the brain’s protective blood barrier becomes leaky with age, starting at the hippocampus, a critical learning and memory center that is damaged by Alzheimer’s disease.
 
The study indicates it may be possible to use brain scans to detect changes in blood vessels in the hippocampus before they cause irreversible damage leading to dementia in neurological disorders characterized by progressive loss of memory, cognition and learning. These findings would have broad implications on conditions that will affect 16 million Americans over age 65 by 2050, according to the latest figures from the Alzheimer’s Association. The research appears in the Jan. 21, 2015, edition of the peer-reviewed scientific journal Neuron.
 
“This is a significant step in understanding how the vascular system affects the health of our brains,” said Berislav V. Zlokovic, M.D., Ph.D., director of the Zilkha Neurogenetic Institute (ZNI) at the Keck School of Medicine, the Mary Hayley and Selim Zilkha Chair for Alzheimer’s Disease Research and the study’s principal investigator. “To prevent dementias including Alzheimer’s, we may need to come up with ways to reseal the blood-brain barrier and prevent the brain from being flooded with toxic chemicals in the blood. Pericytes are the gate-keepers of the blood-brain barrier and may be an important target for prevention of dementia.”
 
Alzheimer’s disease is the most common type of dementia, a general term for loss of memory and other mental abilities. According to the Alzheimer’s Association, roughly 5.2 million people of all ages in the United States today have Alzheimer’s disease, an irreversible, progressive brain disease that causes problems with memory, thinking and behavior. Post-mortem studies of brains with Alzheimer’s disease show damage to the blood-brain barrier, a cellular layer that regulates entry of blood and pathogens into the brain. The reasons why and when this damage occurs, however, remain unclear.
 
In the Neuron study, Zlokovic’s research team examined contrast-enhanced brain images from 64 human subjects of various ages and found that early vascular leakage in the normally aging human brain occurs in the hippocampus, which normally shows the highest barrier properties compared to other brain regions. The blood-brain barrier also showed more damage in the hippocampal area among people with dementia than those without dementia, when controlling for age.
 
To validate the research method, the USC team examined brain scans of young people with multiple sclerosis without cognitive impairment, finding no difference in barrier integrity in the hippocampus between those of the same age with and without the disease. The researchers also looked at the subjects’ cerebrospinal fluid (CSF), which flows through the brain and spinal cord. Individuals who showed signs of mild dementia had 30 percent more albumin, a blood protein, in their CSF than age-matched controls, further indicating a leaky blood-brain barrier. The CSF of individuals with dementia also showed a 115 percent increase of a protein related to pericyte injury. Pericytes are cells that surround blood vessels and help maintain the blood brain barrier; previous research has linked pericytes to dementia and aging.
 
Source: University of Southern California

Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50